Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...
Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared ...
The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months ...
Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.
Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly ...
Agency staff "strongly recommended" a sham surgery-controlled trial be conducted before an approval filing, a stance one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results